<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748370</url>
  </required_header>
  <id_info>
    <org_study_id>VitDTesto1.0</org_study_id>
    <secondary_id>14846</secondary_id>
    <nct_id>NCT01748370</nct_id>
  </id_info>
  <brief_title>Vitamin D Treatment and Hypogonadism in Men</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Androgen Levels in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low total testosterone (TT) is present in about 30% of men aged &gt;60 years and in up to 7% of&#xD;
      younger men. Male hypogonadism is associated with metabolic and cardiovascular diseases as&#xD;
      well as with increased mortality. There is evidence showing a relationship of TT with vitamin&#xD;
      D in men. We aim at evaluating the effect of vitamin D supplementation on TT and metabolic&#xD;
      parameters in hypogonadal men. We will study the effects of 20,000 IU vitamin D weekly in a&#xD;
      12 wk randomized, double-blind, placebo-controlled trial in 100 men with TT &lt;3.0 ng/ml and&#xD;
      25-hydroxyvitamin D (25(OH)D) &lt;30 ng/ml (patients) as well as in 100 men with TT ≥3.0 ng/ml&#xD;
      and 25(OH)D &lt;30 ng/ml (controls). Vitamin D supplementation might be a safe therapeutic&#xD;
      approach improving TT levels as well as metabolic parameters in hypogonadal men. Further the&#xD;
      effects of vitamin D on androgens will be evaluated in eugonadal men.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2012</start_date>
  <completion_date type="Actual">November 12, 2017</completion_date>
  <primary_completion_date type="Actual">November 12, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total testosterone (TT)</measure>
    <time_frame>Change from baseline in TT at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free testosterone (FT)</measure>
    <time_frame>Change from baseline in FT after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance assessed by homeostatic model assessment-insulin resistance (HOMA-IR)</measure>
    <time_frame>Change from baseline in HOMA-IR at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels (total cholesterol)</measure>
    <time_frame>Change from baseline in total cholesterol at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic response during an oral glucose tolerance test (oGTT) as defined by AUCgluc</measure>
    <time_frame>Change from Baseline in AUCgluc at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic response during an oral glucose tolerance test (oGTT) as defined by AUCins</measure>
    <time_frame>Change from Baseline in AUCins at 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Vitamin D hypogonadal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D supplementation in hypogonadal men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D eugonadal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D supplementation in eugonadal men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo hypogonadal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vitamin D supplementation in hypogonadal men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo eugonadal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vitamin D supplementation in eugonadal men</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D supplementation in hypogonadal men</intervention_name>
    <arm_group_label>Vitamin D hypogonadal</arm_group_label>
    <other_name>A11CC05 Colecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D supplementation in eugonadal men</intervention_name>
    <arm_group_label>Vitamin D eugonadal</arm_group_label>
    <other_name>A11CC05 Colecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo hypogonadal</intervention_name>
    <arm_group_label>Placebo hypogonadal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo eugonadal</intervention_name>
    <arm_group_label>Placebo eugonadal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Hypogonadal men:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  TT levels below 3.0 ng/ml (measured at the baseline visit and confirmed at study visit&#xD;
             1)&#xD;
&#xD;
          -  25(OH)D levels below 30 ng/ml (measured at the baseline visit)&#xD;
&#xD;
          -  Male, age of ≥ 18 and &lt;70 years&#xD;
&#xD;
          -  Written informed consent before entered into study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Hypercalcemia defined as a serum calcium &gt; 2,7 mmol/L&#xD;
&#xD;
          -  Oral or transdermal testosterone supplementation in the last 2 months before entering&#xD;
             the study&#xD;
&#xD;
          -  IM testosterone supplementation 6 months before entering the study&#xD;
&#xD;
          -  Regular intake of vitamin D supplements before study entry&#xD;
&#xD;
          -  Men with chronic diseases (such as diabetes mellitus, thyroid disease, endocrine&#xD;
             disturbances in need of treatment (except hypogonadism), or diseases known to&#xD;
             interfere with vitamin D intake or very sensitive to vitamin D intake (such as&#xD;
             inflammatory disease with granuloma: sarcoidoses, tuberculosis, Mb Wegener,&#xD;
             vasculitis, inflammatory bowel disease&#xD;
&#xD;
          -  Intake of medication influencing metabolic or endocrine parameters (insulin&#xD;
             sensitizers, insulin, glucocorticoids,…) in the last 3 months before study entry&#xD;
&#xD;
          -  PSA &gt;4 ng/ml (or &gt;3 ng/ml in men at high risk for prostate cancer) (see state of the&#xD;
             art)&#xD;
&#xD;
          -  Palpable prostate nodule or induration&#xD;
&#xD;
          -  Hematocrit &gt;50%&#xD;
&#xD;
          -  Untreated severe obstructive sleep apnea&#xD;
&#xD;
          -  Severe lower urinary tract symptoms&#xD;
&#xD;
          -  Uncontrolled or poorly controlled heart failure&#xD;
&#xD;
          -  A history of prostate cancer, breast cancer, orchidectomy, chromosomal disorders (e.g.&#xD;
             Klinefelter Syndrome)&#xD;
&#xD;
        Eugonadal men:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  TT levels ≥3.0 ng/ml (measured at the baseline visit and confirmed at study visit 1)&#xD;
&#xD;
          -  25(OH)D levels below 30 ng/ml (measured at the baseline visit)&#xD;
&#xD;
          -  Male, age of ≥ 18 and &lt;70 years&#xD;
&#xD;
          -  Written informed consent before entered into study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypercalcemia defined as a serum calcium &gt; 2,7 mmol/L&#xD;
&#xD;
          -  Oral or transdermal testosterone supplementation in the last 2 months before entering&#xD;
             the study&#xD;
&#xD;
          -  IM testosterone supplementation 6 months before entering the study&#xD;
&#xD;
          -  Regular intake of vitamin D supplements before study entry&#xD;
&#xD;
          -  Men with chronic diseases (such as diabetes mellitus, endocrine disturbances in need&#xD;
             of treatment (except hypogonadism), or diseases known to interfere with vitamin D&#xD;
             intake or very sensitive to vitamin D intake (such as inflammatory disease with&#xD;
             granuloma: sarcoidoses, tuberculosis, Mb Wegener, vasculitis, inflammatory bowel&#xD;
             disease&#xD;
&#xD;
          -  Intake of medication influencing metabolic or endocrine parameters (insulin&#xD;
             sensitizers, insulin, glucocorticoids,…) in the last 3 months before study entry&#xD;
&#xD;
          -  PSA &gt;4 ng/ml (or &gt;3 ng/ml in men at high risk for prostate cancer) (see state of the&#xD;
             art)&#xD;
&#xD;
          -  Palpable prostate nodule or induration&#xD;
&#xD;
          -  Hematocrit &gt;50%&#xD;
&#xD;
          -  Untreated severe obstructive sleep apnea&#xD;
&#xD;
          -  Severe lower urinary tract symptoms&#xD;
&#xD;
          -  Uncontrolled or poorly controlled heart failure&#xD;
&#xD;
          -  A history of prostate cancer, breast cancer, orchidectomy, chromosomal disorders (e.g.&#xD;
             Klinefelter)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Lerchbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>March 17, 2018</last_update_submitted>
  <last_update_submitted_qc>March 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Lerchbaum Elisabeth, MD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>hypogonadism</keyword>
  <keyword>testosterone</keyword>
  <keyword>intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

